Advances in metered dose inhaler technology: Formulation development

AAPS PharmSciTech

Volumn 15, Issue 2, 2014, Pages 434-455

  Myrdal, Paul B ^a   Sheth, Poonam ^a   Stein, Stephen W ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b 3M Drug Delivery Systems 3M Center Building 260 3A 05   (United States)

Author keywords

ethanol; formulation; metered dose inhaler (MDI); propellant; solubilization aids; suspending agents

Indexed keywords

ADRENALIN; ALCOHOL; APAFLURANE; ARFORMOTEROL; AZTREONAM LYSINE; BITOLTEROL MESILATE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; BULKING AGENT; CICLESONIDE; CLARITIN D; CROMOGLYCATE DISODIUM; CRYOFLUORANE; DICHLORODIFLUOROMETHANE; DORNASE ALFA; EPHEDRINE; EXCIPIENT; FENOTEROL PLUS IPRATROPIUM BROMIDE; FLUNISOLIDE; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE; FORMOTEROL FUMARATE; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; ILOPROST; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; ISOETARINE; ISOPRENALINE; LEVALBUTEROL; NEDOCROMIL; NORFLURANE; ORCIPRENALINE; PIRBUTEROL ACETATE; POLYMER; PROPELLANT; RECOMBINANT HUMAN INSULIN; SALBUTAMOL; SALBUTAMOL SULFATE; SALMETEROL XINAFOATE; STABILIZING AGENT; SURFACTANT; TREPROSTINIL; TRIAMCINOLONE ACETONIDE; TRICHLOROFLUOROMETHANE; UNINDEXED DRUG; VOLATILE AGENT;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; METERED DOSE INHALER; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SOLUBILIZATION; SUSPENSION; LUNG; MEDICINAL CHEMISTRY; METABOLISM;

CHEMISTRY, PHARMACEUTICAL; HUMANS; LUNG; METERED DOSE INHALERS;

EID: 84898037878     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-0063-x     Document Type: Review

References (164)

1. Thiel CG. From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. Respir Drug Deliv. 1996;1:115-24.
2. Evans M, Telfer A, Smith R, Smith B, Lang G, Chen J, et al. Stratospheric sink for chlorofluoromethanes: chlorine atomc-atalysed destruction of ozone. Nature. 1974;249:811.
3. McDonald KJ, Martin GP. Transition to CFC-free metered dose inhalers - into the new millennium. Int J Pharm. 2000;201(1):89-107.
4. Newman SP, Peart J. Pressurized metered dose inhalers. In: Newman SP, editor. Respiratory drug delivery: essential theory and practice. Richmond: Respiratory Drug Delivery Online; 2009. p. 117-216.
5. Stein SW, Sheth P, Hodson PD, Myrdal PB. Advances in metered dose inhaler technology: Hardware development. AAPS PharmSciTech. doi: 10.1208/s12249-013- 0062-y
6. Carvalho TC, Peters JI, Williams III RO. Influence of particle size on regional lung deposition - what evidence is there? Int J Pharm. 2011;406(1):1-10.
7. Smyth HDC. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Deliv Rev. 2003;55(7):807-28.
8. Vervaet C, Byron PR. Drug-surfactant-propellant interactions in HFA-formulations. Int J Pharm. 1999;186(1):13-30.
9. McCulloch A. CFC and halon replacements in the environment. J Fluor Chem. 1999;100(1):163-73.
10. Newman SP. Principles of metered-dose inhaler design. Respir Care. 2005;50(9):1177-90.
11. Wallington TJ, Schneider WF, Worsnop DR, Nielsen OJ, Sehested J, Debruyn WJ, et al. The environmental impact of CFC replacements HFCs and HCFCs. Environ Sci Technol. 1994;28(7):320A-6.
12. US Environmental Protection Agency. The process of ozone depletion. Available at: http://www.epa.gov/ozone/science/process.html. Accessed July 17, 2012.
13. United Nations Environment Programme Website. Available at: http://www.unep.org. Accessed June 5, 2013.
14. Federal Registrar. Food and Drug Administration 21 Code of Federal Regulations (2), Use of ozone-depleting substances, Essential-use determination. 2002.
15. Rogueda P, Lallement A, Traini D, Iliev I, Young PM. Twenty years of HFA pMDI patents: facts and perspectives. J Pharm Pharmacol. 2012;64(9):1209-16.
16. Gupte AJ, Bogardus RE, inventors; Richardson Vicks Inc., assignee. Dry aerosol foam. European patent EP 247,608. 1987 Dec 2.
17. Smith IJ. The challenge of reformulation. J Aerosol Med. 1995;8 Suppl 1:S19-27.
18. Dalby RN. Prediction and assessment of flammability hazards associated with metered-dose inhalers containing flammable propellants. Pharm Res. 1992;9(5):636-42.
19. Dalby RN, Byron PR, inventors; Virginia Commonwealth University, assignee. Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants. US patent US 5,202,110. 13 Apr 1993.
20. Decaire B, Ghelani K, Conviser S, Sarrailh S, Le Corre B, Baron C. Materials compatibility testing of new low global warming potential propellants. Respir Drug Deliv Eur. 2011;2:281-4.
21. Knopeck G, Decaire B, Ghelani K. A new generation of aerosol propellants for metered dose inhalers. Respir Drug Deliv. 2010;2:591-4.
22. Sommerville ML, Johnson Jr CS, Cain JB, Rypacek F, Hickey AJ. Lecithin microemulsions in dimethyl ether and propane for the generation of pharmaceutical aerosols containing polar solutes. Pharm Dev Technol. 2002;7(3):273-88.
23. Sommerville ML, Hickey AJ. Aerosol generation by metered-dose inhalers containing dimethyl ether/propane inverse microemulsions. AAPS PharmSciTech. 2003;4(4):455-61.
24. Vega JC, Toneguzzo F, inventors; Laboratorio Pablo Cassera, S.R.L., assignee. Non-ozone depleting medicinal formulations with low greenhouse effect. US patent US 207,685. 16 Aug 2012.
25. Solvay Fluoro GmbH. Solkane 227 pharma and Solkane 134a pharma Product Information. Available at: http://www.solvay-fluor.com. Accessed June 21, 2012.
26. Hoye WL, Mogalian EM, Myrdal PB. Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols. Am J Health-Syst Ph. 2005;62(21):2271-7.
27. Ross DL, Gabrio BJ. Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system. J Aerosol Med. 1999;12(3):151-60.
28. Stein S, Stefely J. Reinventing metered dose inhalers: from poorly efficient CFC MDIs to highly efficient HFA MDIs. Drug Deliv Technol. 2003;3(1):46-51.
29. Stein SW, Cocks PM. Size distribution measurements from metered dose inhalers at low temperatures. Respiratory Drug Delivery Europe. 2013;2:203-8.
30. Williams III R, Liu J. Formulation of a protein with propellant HFA 134a for aerosol delivery. Eur J Pharm Sci. 1999;7(2):137-44.
31. Leach CL. The CFC, to HFA transition and its impact on pulmonary drug development. Respir Care. 2005;50(9):1201-8.
32. Reynolds JM, McNamara DP. Model for moisture transport into inhalation aerosols. Pharm Res. 1996;13(5):809-11.
33. Williams R, Hu C. Investigation of moisture scavengers in pressurized metered-dose inhalers. STP Pharm Sci. 2000;10(3):243-50.
34. Velders GJ, Fahey DW, Daniel JS, McFarland M, Andersen SO. The large contribution of projected HFC emissions to future climate forcing. Proc Natl Acad Sci. 2009;106(27):10949-54.
35. Stein SW, Fradley G. What is the future of MDIs? Respir Drug Deliv. 2010;2:373-6.
36. UNEP Technology and Economic Assessment Panel. Montreal protocol on substances that deplete the ozone layer: TEAP 2010 progress report. Available at: http://www.unep.org. Accessed July 1, 2012.
37. Ding L, Zhang J. Isobutane driven salbutamol sulfate metered dose inhaler: formulation selection and respiratory tract absorption in guinea pigs. Yao Xue Xue Bao. 2009;44(9):1040-5.
38. Moore A. Final report of the safety assessment of isobutane, isopentane, n-butane, and propane. J Am Coll Toxicol. 1982;1:127-42.
39. Aeropres Corporation. MSDS. Available at: http://www.aeropres.com/msds. Accessed June 21, 2013.
40. Corr S, Noakes TJ, inventors; Mexichem Amanco Holding S.A DE C.V, assignee. Compositions comprising salbutamol sulfate. World Intellectual Property Organization patent WO 2013/054135. 2013 Apr 18.
41. Corr S, Noakes TJ, inventors; Mexichem Amanco Holding S.A DE C.V, assignee. Pharmaceutical compositions. World Intellectual Property Organization patent WO 2012/156711. 2012 Nov 22.
42. International Programme on Chemical Safety. 1,1-difluoroethane (HFC-152a) (Screening Information Data Set - SIDs). 2008; Available at: http://inchem.org/. Accessed May 23, 2013.
43. Vance C, Swalwell C, McIntyre IM. Deaths involving 1, 1-difluoroethane at the San Diego County Medical Examiner's Office. J Anal Toxicol. 2012;36(9):626-33.
44. Ernstgård L, Sjögren B, Dekant W, Schmidt T, Johanson G. Uptake and disposition of 1,1-difluoroethane (HFC-152a) in humans. Toxicol Lett. 2012;209(1):21-9.
45. Honeywell International Inc. Solstice propellant technical brochure. Available at: http://honeywell-solstice-propellants.com. Accessed June 17, 2012.
46. Dupont. Opteon YF FAQ. Available at: http://www2.dupont.com. Accessed June 17, 2012.
47. Leach CL, Kuehl PJ, Chand R, Ketai L, Norenberg JP, McDonald JD. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol. 2012;108(3):195-200.
48. Dalby RN, Byron PR. Comparison of output particle size distributions from pressurized aerosols formulated as solutions or suspensions. Pharm Res. 1988;5(1):36-9.
49. Noakes T. Medical aerosol propellants. J Fluor Chem. 2002;118(1):35-45.
50. U.S. Food and Drug Administration. Inactive Ingredient Search for Approved Drug Products. 2013; Available at: http://www.accessdata.fda.gov/ scripts/cder/iig/. Accessed June 21, 2013.
51. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed June 21, 2013.
52. Grainger C, Saunders M, Buttini F, Telford R, Merolla L, Martin G, et al. Critical characteristics for corticosteroid solution metered dose inhaler bioequivalence. Mol Pharm. 2012;9(3):563-9.
53. Riley T, Christopher D, Arp J, Casazza A, Colombani A, Cooper A, et al. Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs). AAPS PharmSciTech. 2012;13(3):978-89.
54. Hoye JA, Myrdal PB. Measurement and correlation of solute solubility in HFA-134a/ethanol systems. Int J Pharm. 2008;362(1):184-8.
55. Stein SW, Myrdal PB. The relative influence of atomization and evaporation on metered dose inhaler drug delivery efficiency. Aerosol Sci Tech. 2006;40(5):335-47.
56. Gupta A, Stein SW, Myrdal PB. Balancing ethanol cosolvent concentration with product performance in 134a-based pressurized metered dose inhalers. J Aerosol Med. 2003;16(2):167-74.
57. Myrdal PB, Karlage KL, Stein SW, Brown BA, Haynes A. Optimized dose delivery of the peptide cyclosporine using hydrofluoroalkane-based metered dose inhalers. J Pharm Sci. 2004;93(4):1054-61.
58. Mogalian E, Myrdal PB. Application of USP inlet extensions to the TSI impactor system 3306/3320 using HFA 227 based solution metered dose inhalers. Drug Dev Ind Pharm. 2005;31(10):977-85.
59. Saleem IY, Smyth HD. Tuning aerosol particle size distribution of metered dose inhalers using cosolvents and surfactants. BioMed Res Int. 2013. doi: 10.1155/2013/574310.
60. Stein SW, Gabrio BJ. Understanding throat deposition during cascade impactor testing. Respir Drug Deliv. 2000;2:287-90.
61. Stein SW, Myrdal PB. A theoretical and experimental analysis of formulation and device parameters affecting solution MDI size distributions. J Pharm Sci. 2004;93(8):2158-75.
62. Sheth P, Stein SW, Myrdal PB. The influence of initial atomized droplet size on residual particle size from pressurized metered dose inhalers. Int J Pharm. 2013;455(1-2):57-65.
63. Warren SJ, Farr SJ. Formulation of solution metered dose inhalers and comparison with aerosols emitted from conventional suspension systems. Int J Pharm. 1995;124(2):195-203.
64. Stein SW, Forsyth BR, Stefely JS, Christensen JD, Alband TD, Jinks PA. Expanding the dosing range of metered dose inhalers through formulation and hardware optimization. Respir Drug Deliv. 2004;1:125-34.
65. Scherrer RA, Stefely JS, Stein SW, inventors; 3M Innovative Properties Company, assignee. Medicinal aerosol formulations comprising ion pair complexes. World Intellectual Property Organization patent WO 2003/059316. 24 Jul 2003.
66. Stefely JS, Duan DC, Myrdal PB, Ross DL, Schultz DW, Leach CL. Design and utility of a novel class of biocompatible excipients for HFA based MDIs. Respir Drug Deliv. 2000;1:83-90.
67. Stefely JS, Brown BA, Hammerbeck DM, Stein SW. Equipping the MDI for the 21st century by expanding its formulation options. Respir Drug Deliv. 2002;1:207-14.
68. Stefely JS, Duan DC, inventors; 3M Innovative Properties Company, assignee. Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient. US patent US 7,718,162. 18 May 2010.
69. Rogueda P, inventor; AstraZeneca, assignee. Pharmaceutical spray formulation comprising a hypro fluor alkane amd an acylated cyclodextrin. World Intellectual Property Organization patent WO 2005/053637. 16 Jun 2005.
70. Tashkin DP. Extra-fine corticosteroid aerosols from hydrofluoroalkane- 134a metered-dose inhalers: potential advantages and disadvantages. Chest. 1999;115(2):316-8.
71. ®: improving the changeover to CFC-free treatments. Respir Med. 2003;97(Suppl D):S1-3.
72. ®: a simple solution to a difficult problem. Respiration. 2005;72 Suppl 1:3-5.
73. Ganderton D, Lewis D, Davies R, Meakin B, Church T. The formulation and evaluation of a CFC-free budesonide pressurised metered dose inhaler. Respir Med. 2003;97:S4-9.
74. Majury C, Tran CH, Taylor G. Assessing the influence of ethanol on the aerosol properties of beclomethasone pMDIs using the next generation impactor. Respir Drug Deliv. 2012;2:433-6.
75. Chaplin S, Head S. Clenil Modulite, a CFC-free MDI with no adjustment on switching. Prescriber. 2007;18(13):43-6.
76. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol. 1999;104(6):1215-22.
77. Lipworth B. Targeting the small airways asthma phenotype: If we can reach it, should we treat it? Ann Allergy Asthma Immonol. 2013;110(4):233-9.
78. Leach C, Davidson P, Boudreau R. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12(6):1346-53.
79. Price D, Thomas M, Haughney J, Lewis RA, Burden A, von Ziegenweidt J, et al. Real-life comparison of beclometasone dipropionate as an extrafine-or larger-particle formulation for asthma. Respir Med. 2013. doi: 10.1016/j.rmed.2013.03.009.
80. Robinson CA, Tsourounis C. Inhaled corticosteroid metered-dose inhalers: how do variations in technique for solutions versus suspensions affect drug distribution? Ann Pharmacother. 2013;47(3):416-20.
81. Barnes N, Price D, Colice G, Chisholm A, Dorinsky P, Hillyer E, et al. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy. 2011;41(11):1521-32.
82. Church TK, Lewis DA, Ganderton D, Meakin BJ, Brambilla G, inventors; Chiesi Farmaceutici S.p.A, assignee. Salmeterol superfine formulation. US patent US 8,088,362. 3 Jan 2012.
83. Lewis D, Ganderton D, Meakin B, Brambilla G, Ferraris A, inventors; Cheiesi Farmaceutici S.p.A., assignee. Stable pharmaceutical solution formulations for pressurized metered dose inhalers. US patent US 7,018,618. 28 Mar 2006.
84. Tzou T, Pachuta RR, Coy RB, Schultz RK. Drug form selection in albuterol-containing metered-dose inhaler formulations and its impact on chemical and physical stability. J Pharm Sci. 1997;86(12):1352-7.
85. Stank K, Steckel H. Physico-chemical characterisation of surface modified particles for inhalation. Int J Pharm. 2013;114:9-18.
86. Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev. 2006;58(9):1009-29.
87. Chow AH, Tong HH, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24(3):411-37.
88. Murnane D, Martin GP, Marriott C. Investigations into the formulation of metered dose inhalers of salmeterol xinafoate and fluticasone propionate microcrystals. Pharm Res. 2008;25(10):2283-91.
89. Jones SA, Martin GP, Brown MB. Manipulation of beclomethasone- hydrofluoroalkane interactions using biocompatible macromolecules. J Pharm Sci. 2006;95(5):1060-74.
90. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392(1):1-19.
91. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50(9):1209-27.
92. Malcolmson RJ, Embleton JK. Dry powder formulations for pulmonary delivery. Pharm Sci Technol Today. 1998;1(9):394-8.
93. Li H, Seville PC. Novel pMDI formulations for pulmonary delivery of proteins. Int J Pharm. 2010;385(1):73-8.
94. Li H, Song X, Seville PC. The use of sodium carboxymethylcellulose in the preparation of spray-dried proteins for pulmonary drug delivery. Eur J Pharm Sci. 2010;40(1):56-61.
95. Liao Y, Brown MB, Jones SA, Nazir T, Martin GP. The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers. Int J Pharm. 2005;304(1):29-39.
96. Jones SA, Martin GP, Brown MB. Stabilisation of deoxyribonuclease in hydrofluoroalkanes using miscible vinyl polymers. J Control Release. 2006;115(1):1-8.
97. Tam JM, Engstrom JD, Williams III RO, Johnston KP. Suspensions of protein and poorly water soluble drug particles for high dosages with pressurized metered dose inhalers. Respir Drug Deliv. 2008;3:931-6.
98. Tan Y, Yang Z, Peng X, Xin F, Xu Y, Feng M, et al. A novel bottom-up process to produce nanoparticles containing protein and peptide for suspension in hydrofluoroalkane propellants. Int J Pharm. 2011;413(1):167-73.
99. Selvam P, El-Sherbiny IM, Smyth HD. Swellable hydrogel particles for controlled release pulmonary administration using propellant-driven metered dose inhalers. J Aerosol Med. 2011;24(1):25-34.
100. Longest PW, Hindle M. Numerical model to characterize the size increase of combination drug and hygroscopic excipient nanoparticle aerosols. Aerosol Sci Tech. 2011;45(7):884-99.
101. Williams III RO, Barron MK, Alonso MJ, Remuñán-López C. Investigation of a pMDI system containing chitosan microspheres and P134a. Int J Pharm. 1998;174(1):209-22.
102. Haghi M, Bebawy M, Colombo P, Forbes B, Lewis D, Salama R, et al. Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles in vitro. Eur J Pharm Biopharm. 2013. doi: 10.1016/j.ejpb.2013.02.020.
103. O'Donnell KP, Williams III RO. Pulmonary dispersion formulations: The impact of dispersed powder properties on pressurized metered dose inhaler stability. Drug Dev Ind Pharm. 2013;39(3):413-24.
104. Rogueda PG, Buckin V, Kudryashov E. Size and concentration monitoring of HFA suspensions. Respir Drug Deliv. 2006;2:453-6.
105. Lechuga-Ballesteros D, Noga B, Vehring R, Cummings RH, Dwivedi SK. Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma. Futur Med Chem. 2011;3(13):1703-18.
106. Sukasamea N, Boonmea P, Srichanaa T. Development of budesonide suspensions for use in an HFA pressurized metered dose inhaler. ScienceAsia. 2011;37(1):31-7.
107. Rogueda P. Novel hydrofluoroalkane suspension formulations for respiratory drug delivery. Expert Opin Drug Deliv. 2005;2(4):625-38.
108. Stein SW, Sheth P, Karayiannis C, Chiou H, Myrdal PB. Modeling MDI delivery: A priori predictions, empirical models and experiments. Respir Drug Deliv. 2010;1:353-64.
109. Stein SW, Sheth P, Myrdal PB. A model for predicting size distributions delivered from pMDIs with suspended drug. Int J Pharm. 2012;422(1):101-15.
110. Berry J, Kline LC, Sherwood JK, Chaudhry S, Obenauer-Kutner L, Hart JL, et al. Influence of the size of micronized active pharmaceutical ingredient on the aerodynamic particle size and stability of a metered dose inhaler. Drug Dev Ind Pharm. 2004;30(7):705-14.
111. Sharpe SA, Sequeira JA, inventors; Schering Corporation, assignee. Metered dose inhaler containing an aerosol suspension formulation. European patent EP 1,785,156. 2012 Jun 27.
112. Sherwood JK, Alex S, Salama G, Obenauer-Kutner L, Huyck S, Berry J, et al. Particle size coarsening induced by valve silicone in a metered dose inhaler. Drug Dev Ind Pharm. 2007;33(2):155-62.
113. Berry J, Kline L, Naini V, Chaudhry S, Hart J, Sequeira J. Influence of the valve lubricant on the aerodynamic particle size of a metered dose inhaler. Drug Dev Ind Pharm. 2004;30(3):267-75.
114. James J, Davies M, Toon R, Jinks P, Roberts CJ. Particulate drug interactions with polymeric and elastomeric valve components in suspension formulations for metered dose inhalers. Int J Pharm. 2009;366(1):124-32.
115. Ridder KB, Davies-Cutting CJ, Kellaway IW. Surfactant solubility and aggregate orientation in hydrofluoroalkanes. Int J Pharm. 2005;295(1):57-65.
116. da Rocha SR, Bharatwaj B, Saiprasad S. Science and technology of pressurized metered-dose inhalers. In: Smyth HDC, Hickey AJ, editors. Controlled pulmonary drug delivery. New York: Springer; 2011. p. 165-201.
117. ®: product Information. Available at: http://worldaccount.basf.com/wa/NAFTA∼en-US/ Catalog/ChemicalsNAFTA/pi/BASF/Brand/pluronic. Accessed July 7, 2013.
118. Alexandridis P, Alan HT. Poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: thermodynamics, structure, dynamics, and modeling. Colloids Surf A Physicochem Eng Asp. 1995;96(1):1-46.
119. Griffin WC. Calculation of HLB values of non-ionic surfactants. Am Perfumer Essent Oil Rev. 1955;65:26-9.
120. Sommerville ML, Cain JB, Johnson Jr CS, Hickey AJ. Lecithin inverse microemulsions for the pulmonary delivery of polar compounds utilizing dimethylether and propane as propellants. Pharm Dev Technol. 2000;5(2):219-30.
121. Sheth P, Myrdal PB. Polymers for pulmonary drug delivery. In: Smyth HDC, Hickey AJ, editors. Controlled pulmonary drug delivery. New York: Springer; 2011. p. 265-82.
122. Leach CL, Hameister WM, Tomaie MA, Hammerbeck DM, Stefely JS. Oligolactic acid (OLA) biomatrices for sustained release of asthma therapeutics. Respir Drug Deliv. 2000;1:75-82.
123. Traini D, Young P, Rogueda P, Price R. Investigation into the influence of polymeric stabilizing excipients on inter-particulate forces in pressurised metered dose inhalers. Int J Pharm. 2006;320(1):58-63.
124. Wu L, da Rocha SR. Biocompatible and biodegradable copolymer stabilizers for hydrofluoroalkane dispersions: a colloidal probe microscopy investigation. Langmuir. 2007;23(24):12104-10.
125. Rogueda PG. Pushing the boundaries: searching for novel HFA suspension formulations. Respir Drug Deliv. 2004;1:117-24.
126. Looker BE, Lunniss CJ, Redgrave AJ, inventors; Glaxo Group Limited, assignee. Compounds for use as surfactants. World Intellectual Property Organization patent WO 2003/035237. 1 May 2003.
127. Looker BE, Lunniss CJ, Redgrave A, inventors; Glaxo Group Limited, assignee. Carboxylic acid compounds for use as surfactants. World Intellectual Property Organization patent WO 2003/068722. 21 Aug 2003.
128. Berry J, Chaudry IA, Sequeira JA, Kopcha M, inventors; Schering Corporation, assignee. Non-chlorofluorocarbon aerosol formulations. European patent EP 0656206. 4 June 1995.
129. Tan Y, Yang Z, Pan X, Chen M, Feng M, Wang L, et al. Stability and aerosolization of pressurized metered dose inhalers containing thymopentin nanoparticles produced using a bottom-up process. Int J Pharm. 2012;427(2):385-92.
130. Kellaway IW, Taylor K, Nyambura BK, inventors; School of Pharmacy, University of London, assignee. Formulations for delivery via pressurised metered dose inhalers comprising an essential oil as suspension stabiliser. European patent EP 2,089,008. 20 Jul 2011.
131. Byron PR, Blondino FE. Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent 1996.
132. Byron P, Blondino F inventors; The Center for Innovative Technology, Virginia Commonwealth University, assignees. Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant. US patent US 5,492,688. 20 Feb 1996.
133. Cantor AS, Stefely JS, Jinks PA, Baran JR, Ganser JM, Mueting MW, et al. Modifying interparticulate interactions using surface-modified excipient nanoparticles. Respir Drug Deliv. 2008;1:309-18.
134. Sharma K, Somavarapu S, Colombani A, Govind N, Taylor KM. Crosslinked chitosan nanoparticle formulations for delivery from pressurized metered dose inhalers. Eur J Pharm Biopharm. 2012;81(1):74-81.
135. Steckel H, Wehle S. A novel formulation technique for metered dose inhaler (MDI) suspensions. Int J Pharm. 2004;284(1):75-82.
136. Sawatdee S, Phetmung H, Srichana T. Sildenafil citrate monohydrate-cyclodextrin nanosuspension complexes for use in metered-dose inhalers. Int J Pharm. 2013. doi: 10.1016/j.ijpharm.2013.07.023.
137. Wu L, Al-Haydari M, da Rocha SR. Novel propellant-driven inhalation formulations: engineering polar drug particles with surface-trapped hydrofluoroalkane-philes. Eur J Pharm Sci. 2008;33(2):146-58.
138. Wu L, Bharatwaj B, Panyam J, da Rocha SR. Core-shell particles for the dispersion of small polar drugs and biomolecules in hydrofluoroalkane propellants. Pharm Res. 2008;25(2):289-301.
139. Chokshi U, Selvam P, Porcar L, da Rocha SR. Reverse aqueous emulsions and microemulsions in HFA227 propellant stabilized by non-ionic ethoxylated amphiphiles. Int J Pharm. 2009;369(1):176-84.
140. Selvam P, Bharatwaj B, Porcar L, da Rocha SR. Reverse aqueous microemulsions in hydrofluoroalkane propellants and their aerosol characteristics. Int J Pharm. 2012;422(1):428-35.
141. Butz N, Porte C, Courrier H, Krafft M, Vandamme TF. Reverse water-in-fluorocarbon emulsions for use in pressurized metered-dose inhalers containing hydrofluoroalkane propellants. Int J Pharm. 2002;238(1):257-69.
142. Patel N, Marlow M, Lawrence MJ. Formation of fluorinated nonionic surfactant microemulsions in hydrofluorocarbon 134a (HFC 134a). J Colloid Interface Sci. 2003;258(2):345-53.
143. ® D HFA preparations. Chem Pharm Bull. 2006;54(9):1276-80.
144. ® D hydrofluoroalkane preparations (2). Chem Pharm Bull. 2012;60(5):593-7.
145. Adjei A, Cutie AJ, inventors. Medicinal aerosol formulation. US patent US 6,261,539. 17 Jul 2001.
146. DeStefano G, Kelash-Cannova LJ, inventors; Boehringer Ingelheim Pharmaceutics, Inc., assignee. Formulation for metered dose inhaler using hydro-fluoro-alkanes as propellants. US patent US 7,914,770. 29 Mar 2011.
147. Neale PJ, Taylor AJ, inventors; Glaxo Group Limited, assignee. Medicaments for treating respiratory disorders. United States patent US 5,688,782. 1997 Nov 18.
148. Dellamary LA, Tarara TE, Smith DJ, Woelk CH, Adractas A, Costello ML, et al. Hollow porous particles in metered dose inhalers. Pharm Res. 2000;17(2):168-74.
149. Weers JG, Tarara TE, Malcolmson RJ, Leung D. Embedded crystals in low density particles: formulation, manufacture, and properties. Respir Drug Deliv. 2006;1:297-306.
150. Tarara TE, Hartman MS, Gill H, Kennedy AA, Weers JG. Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a. Pharm Res. 2004;21(9):1607-14.
151. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology. J Aerosol Med. 2011;24(4):175-82.
152. Jinks PA. Preparation and utility of sub-micron lactose, a novel excipient for HFA MDI suspension formulations [abstract]. Drug Del to the Lungs, 14. 2003.
153. James J, Crean B, Davies M, Toon R, Jinks P, Roberts CJ. The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers. Int J Pharm. 2008;361(1):209-21.
154. Adjei A, Cutie AJ, inventors; Aeropharm Technology Incorporated, assignee. Medicinal aerosol formulation. European patent EP 1,731,140. 13 Apr 2011.
155. Toneguzzo F, Vega JC, inventors; Laboratorio Pablo Cassara S.R.L., assignee. Stabilized metered dose inhaler. US patent US 104,488. 2 My 2013.
156. Jones R, Evans RM, Warren SJ, Taylor G. Development of a fluticasone propionate suspension pMDI formulation using a second particulate system. Respir Drug Deliv. 2004;2:401-4.
157. Jones R, Evans RM, Warren SJ, Taylor G. Development of a novel suspension MDI formulation using a low energy dispersion system. Respir Drug Deliv. 2002;2:799-802.
158. Young PM, Adi H, Patel T, Law K, Rogueda P, Traini D. The influence of micronised particulates on the aerosolisation properties of pressurised metered dose inhalers. J Aerosol Sci. 2009;40(4):324-37.
159. Johnson M. Inhaled corticosteroid - long-acting ß2-agonist synergism: therapeutic implications in human lung disease. Respir Drug Deliv. 2004;1:99-108.
160. Kaerger JS, Price R. Processing of spherical crystalline particles via a novel solution atomization and crystallization by sonication (SAXS) technique. Pharm Res. 2004;21(2):372-81.
161. Adi H, Young PM, Traini D. Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers. J Pharm Pharmacol. 2012;64(9):1245-53.
162. Rogueda PG, Price R, Smith T, Young PM, Traini D. Particle synergy and aerosol performance in non-aqueous liquid of two combinations metered dose inhalation formulations: an AFM and Raman investigation. J Colloid Interface Sci. 2011;361(2):649-55.
163. Vehring R, Lechuga-Ballesteros D, Joshi V, Noga B, Dwivedi SK. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28(42):15015-23.
164. Noga B, Cummings H, Joshi V, Lechuga-Ballesteros D, Schultz RD, Speck JH, et al. Product performance, stability and dose proportionality of glycopyrrolate metered dose inhaler with sub-microgram doses using Pearl cosuspension technology. Respir Drug Deliv. 2012;2:645-8.